AAIC 2026: Biomarker-Guided Clinical Trials

Biomarker-Guided Clinical Trials at AAIC 2026

AAIC 2026 highlighted the transformative role of biomarkers in [Alzheimer's disease](/diseases/alzheimers-disease) (AD) clinical trials, from patient selection to outcome measures and regulatory approval. Biomarker-guided approaches are now essential for efficient trial design and successful therapeutic development.

Biomarker-Based Patient Selection

Amyloid-Positive Enrichment

Selecting patients based on biomarker confirmation[@cummings2024]:

• Anti-amyloid trials: Requiring amyloid PET positivity or CSF biomarker evidence
• Impact on trial efficiency: Reduced sample sizes and shorter trial durations
• Diversity considerations: Ensuring biomarker criteria don't exclude diverse populations

Tau PET Stratification

Utilizing [tau](/proteins/tau) pathology for patient stratification:

• Baseline tau burden: Predicting treatment response
• Regional tau targeting: Matching patients to specific mechanisms
• Tau spread patterns: Identifying therapeutic targets

Blood Biomarker Screening

Revolutionizing trial recruitment:

• Pre-screening with [p-Tau217](/biomarkers/p-tau-217)/p-Tau181: Identifying amyloid-positive individuals
• Reducing screening failure rates: Up to 70% reduction in screen failures
• Cost implications: Significant cost savings in recruitment

Surrogate Endpoints

Amyloid Clearance

Measuring biological effects of anti-amyloid therapies[@mintun2021]:

Biomarker-Guided Clinical Trials at AAIC 2026

AAIC 2026 highlighted the transformative role of biomarkers in [Alzheimer's disease](/diseases/alzheimers-disease) (AD) clinical trials, from patient selection to outcome measures and regulatory approval. Biomarker-guided approaches are now essential for efficient trial design and successful therapeutic development.

Biomarker-Based Patient Selection

Amyloid-Positive Enrichment

Selecting patients based on biomarker confirmation[@cummings2024]:

• Anti-amyloid trials: Requiring amyloid PET positivity or CSF biomarker evidence
• Impact on trial efficiency: Reduced sample sizes and shorter trial durations
• Diversity considerations: Ensuring biomarker criteria don't exclude diverse populations

Tau PET Stratification

Utilizing [tau](/proteins/tau) pathology for patient stratification:

• Baseline tau burden: Predicting treatment response
• Regional tau targeting: Matching patients to specific mechanisms
• Tau spread patterns: Identifying therapeutic targets

Blood Biomarker Screening

Revolutionizing trial recruitment:

• Pre-screening with [p-Tau217](/biomarkers/p-tau-217)/p-Tau181: Identifying amyloid-positive individuals
• Reducing screening failure rates: Up to 70% reduction in screen failures
• Cost implications: Significant cost savings in recruitment

Surrogate Endpoints

Amyloid Clearance

Measuring biological effects of anti-amyloid therapies[@mintun2021]:

• PET amyloid reduction: Centiloid change as endpoint
• CSF biomarker changes: [Aβ42](/proteins/amyloid-beta)/40 ratio normalization
• Time course: Relationship between amyloid removal and clinical outcomes

Tau Modification

Emerging tau-focused endpoints:

• Tau PET change: Regional tau burden modification
• Fluid tau biomarkers: p-Tau changes as surrogate
• Neurodegeneration markers: NfL as downstream marker

Neurodegeneration Biomarkers

General markers of disease modification:

• Brain atrophy rates: MRI volumetric changes
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain: NfL as marker of neuronal injury
• Synaptic biomarkers: SV2A PET, NPTX1

Adaptive Trial Designs

Biomarker-Driven Adaptations

Flexible trial designs incorporating biomarker data:

• Sample size re-estimation: Based on biomarker effect size
• Arm dropping: Eliminating non-effective doses
• Enrichment adaptations: Focusing on responsive subgroups

Platform Trials

Master protocol approaches:

• MASTER AD protocol: Multi-arm platform for AD
• Adaptive randomization: Based on interim biomarker results
• Efficient resource utilization: Shared control arms

Regulatory Perspectives

FDA Guidance

Regulatory acceptance of biomarkers:

• Accelerated approval: Using amyloid PET as surrogate endpoint
• Clinical trial endpoints: Biomarker changes supporting approval
• Label expansions: Including biomarker data in prescribing information

EMA Perspectives

European regulatory considerations:

• Biomarker qualification: Pathway for novel biomarkers
• Conditional approvals: Based on biomarker evidence
• Post-marketing requirements: Continued biomarker monitoring

Specific Trial Updates

Anti-Amyloid Monoclonal Antibodies

Recent trial results with biomarker endpoints:

• Leucanemab (Leqembi): CLARITY-AD biomarker findings
• [Donanemab](/entities/donanemab) (Kisunla): TRAILBLAZER-ALZ 2 biomarker data
• Aduhelm legacy: Lessons learned from approval process

Anti-Tau Therapies

Tau-targeted approaches:

• Active vaccination: ACI-35 and other tau vaccines
• Passive immunization: Anti-tau antibodies
• Small molecule inhibitors: Tau aggregation blockers

Neuroprotection Strategies

Disease-modifying approaches beyond amyloid and tau:

• [TREM2](/proteins/trem2) modulators: Microglial-targeted therapies
• Neuroinflammation inhibitors: Anti-inflammatory approaches
• Synaptic protection: Synaptic resilience strategies

Combination Therapies

Rationale for Combination Approaches

Multiple pathways require multiple interventions:

• Amyloid + tau: Targeting both pathologies
• Pathology + neuroprotection: Comprehensive approaches
• Personalized combinations: Based on individual biomarker profiles

Biomarker Monitoring for Combinations

Optimizing combination therapy:

• Biomarker interactions: Effects of combinations on multiple targets
• Safety monitoring: Biomarker-guided safety assessments
• Dosing optimization: Adaptive dosing based on biomarkers

Precision Medicine Approaches

Subtype-Specific Trials

Targeting biomarker-defined subtypes:

• By amyloid status: Sporadic vs. autosomal dominant AD
• By tau pattern: Regional tau subtypes
• By comorbidities: Vascular, Lewy body comorbidities

Personalized Trial Designs

Individualized therapeutic approaches:

• N-of-1 trials: Single-patient optimization
• Biomarker trajectories: Individual response patterns
• Adaptive sequencing: Sequential treatments based on biomarkers

Cost-Effectiveness Analysis

Biomarker-Driven Healthcare Economics

Economic implications of biomarker-guided care:

• Early diagnosis cost savings: Downstream cost reductions
• Treatment efficiency: Better allocation of expensive therapies
• Prevention cost-effectiveness: Investing in early intervention

Real-World Evidence

Post-approval biomarker monitoring:

• Registry data: Long-term biomarker outcomes
• Clinical practice biomarkers: Real-world implementation
• Health economic models: Population-level impacts

Future Directions

Emerging Biomarkers

New markers in development:

• Synaptic dysfunction markers: Direct measurement of synaptic loss
• Cellular senescence markers: Senolytic targets
• [Microbiome](/entities/microbiome) markers: [Gut-brain axis](/entities/gut-brain-axis) biomarkers

Trial Design Innovation

Next-generation approaches:

• Preventive trials: Initiating treatment in preclinical stages
• Outcome measure innovation: Novel clinical and biomarker composites
• Global trial networks: International collaboration

Overview

This page provides information about AAIC 2026: Biomarker-Guided Clinical Trials.

See Also

• [NeuroWiki Home](/home)

References